QV Bioelectronics

Who We Are

Founded by experts in neurosurgery, oncology, and medical engineering, we bring together a highly technical, multi-disciplinary team shaped by experience at the worldʼs leading research institutions. Backed by leading investors and collaborators, we are committed to increasing the number of long-term survivors in cancer.

Why Electric Fields?

Meet GRACE – The Future of Cancer Treatment

GRACE is a platform for the next generation of cancer therapy. By delivering therapeutic electric fields from within the body, it opens new possibilities for tackling some of the hardest to treat cancers. This technology forms the foundation for a pipeline of implantable therapies adaptable across multiple indications, with our first target in glioblastoma.

Continuous Treatment

Cancer doesnʼt rest, and neither should treatment. Because GRACE is fully implantable, it allows therapy to be delivered continuously. Where traditional treatments act for limited windows before their effects wear off, implantable electric fields sustain therapy around the clock.

Targeted Therapy

GRACE delivers therapy directly where itʼs needed in the brain. By focusing electric fields on dividing tumour cells, treatment is localised to the cancer site and reduces impact on the rest of the body. The result is a precise approach designed to fight the tumour while sparing healthy tissue.

Designed for Life

Life does not stop with a diagnosis. GRACE is designed to fit naturally into daily routines with minimal external parts, so patients can stay active, independent, and connected to the things they love. By working in the background while patients go about their day, it supports quality of life without interrupting effective therapy.

Our Pipeline

Unlocking the Next Frontier in Cancer Treatment

Glioblastoma is only the beginning. Using the same technology and device, our platform has the potential to transform treatment across a range of aggressive cancers, from paediatric tumours to widespread brain metastases and beyond.

Feasibility

Preclinical Testing

Design & Development

Validation

Phase 1

Glioblastoma80%80%

Diffuse Midline Glioma80%80%

Brain Metastases50%50%

Pancreatic Cancer20%20%

Gall Bladder Cancer20%20%

Oesophageal Cancer18%18%

Leadership

Dr Chris Bullock

CEO & Co-Founder

Dr Richard Fu

Clinical Director & Co-Founder

Carl Daintree

COO

Sabine Ficek

CFO

Alastair Atkinson

Executive Chairman

Deepak Kotak

Non-Executive Director

Clinical Advisory Panel

Professor Paul Brennan

Professor of Clinical & Experimental Neurosurgery & Hon. Consultant Neurosurgeon
University of Edinburgh and NHS Lothian

Dr. Kenny Kwok Hei Yu

Neurosurgeon
Memorial Sloan Kettering Cancer Center

Professor Hani Marcus

Professor of Neurosurgery and Consultant Neurosurgeon
NHNN & UCL Queen Square Institute of Neurology

Mr. Rasheed Zakaria

Honorary Consultant Neurosurgeon & Senior Clinical Lecturer
Walton Centre NHS FT / Univ. of Liverpool

Professor Florian Gessler

Vice Chairman, Department of Neurosurgery
University Hospital of Rostock

Professor Kate Drummond

Director of Neurosurgery at Royal Melbourne Hospital and Head of Central Nervous System Tumours at the VCCC Parkville Precinct

Professor Stephen Price

Professor of Neurosurgical Oncology & Hon. Consultant
University of Cambridge

Professor Mark Plazier

Neurosurgeon Jessa Hospital Hasselt
Professor, University Hasselt Belgium

Dr. Tony Van Havenburgh

Chairman, Department of Neurosurgery
University of Antwerp

Dr. Thomas Kriesen

Head of Functional Neurosurgery University Hospital of Rostock

Mr Vejay N. Vakharia

Consultant Neurosurgeon
Alder Hey Children’s Hospital

Dr. Joshua Bernstock

Neurosurgeon
Brigham & Women’s Institute & Boston Children’s Hospitals